Hot Blue Chip Stocks To Own For 2019

Much has been made of the stock market’s record-setting performance since President Donald Trump won the race for the White House back in November.

Read: Yellen may have the clearest explanation for the stock market’s record run

But Dow Jones’s data team offers more insight into how Trump stacks up compared with other presidents in their first 30 days in office, a milepost Trump hits on Feb. 19. The Dow Jones Industrial Average
DJIA, +0.02%
has returned 4.02% as of Friday’s close, which would make the Dow’s performance in the Trump era’s first month the sixth best in percentage terms behind Franklin D. Roosevelt in 1945, after his fourth victorious campaign for the presidency, when blue chips climbed by 4.1%.

Hot Blue Chip Stocks To Own For 2019: Fortress Transportation and Infrastructure Investors LLC(FTAI)

Advisors’ Opinion:

  • [By Logan Wallace]

    These are some of the media stories that may have effected Accern Sentiment’s scoring:

    Fortress Transportation and Infrastructure Investors (FTAI) Lifted to B- at TheStreet (americanbankingnews.com) BidaskClub Upgrades Fortress Transportation and Infrastructure Investors (FTAI) to “Buy” (americanbankingnews.com) Active Mover – Fortress Transportation and Infrastructure Investors LLC (NYSE: FTAI) (alphabetastock.com) Services Stock Buzz: Fortress Transportation and Infrastructure Investors LLC (FTAI) (stocksgeeks.com) Contrasting H&E Equipment Services (HEES) & Fortress Transportation and Infrastructure Investors (FTAI) (americanbankingnews.com)

    Shares of FTAI opened at $16.25 on Friday. The stock has a market cap of $1,365.03, a PE ratio of 135.42 and a beta of 1.56. Fortress Transportation and Infrastructure Investors has a 12-month low of $14.25 and a 12-month high of $20.13.

  • [By Shane Hupp]

    Fortress Transprtn and Infr Investrs (NYSE: FTAI) and WillScot (NASDAQ:WSC) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends and profitability.

Hot Blue Chip Stocks To Own For 2019: Baidu Inc.(BIDU)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    In this segment from the Motley Fool Money podcast, host Chris Hill is joined by Jason Moser of Million Dollar Portfolio, David Kretzmann of Hidden Gems Canada, and Aaron Bush of Motley Fool Rule Breakers to address a listener’s question: What’s the best Chinese stock for long-term investors? The team likes Baidu (NASDAQ:BIDU), commonly referred to as “the Google of China,” as well as Tencent (NASDAQOTH:TCEHY), the company behind the extremely popular messaging and social media app WeChat.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    ReTo Eco-Solutions, Inc. (NASDAQ: RETO) fell 9.3 percent to $4.50 in pre-market trading.
    ProPhase Labs, Inc. (NASDAQ: PRPH) shares fell 8.5 percent to $4.50 in pre-market trading after dropping 3.53 percent on Thursday.
    Nordstrom, Inc. (NYSE: JWN) fell 7.5 percent to $47.10 in pre-market trading. Nordstrom reported upbeat results for its first quarter. Comparable-store sales rose 0.6 percent.
    Baidu, Inc. (NASDAQ: BIDU) shares fell 6 percent to $263.00 in pre-market trading. Baidu disclosed that its COO Qi Lu will step down in July 2018.
    Riot Blockchain, Inc. (NASDAQ: RIOT) shares fell 5.6 percent to $8.98 in pre-market trading after climbing 11.88 percent on Thursday.
    Applied Materials, Inc. (NASDAQ: AMAT) fell 5 percent to $51.30 in pre-market trading. Applied Materials reported stronger-than-expected results for its second quarter, but issued weak sales outlook for the third quarter.
    Blink Charging Co. (NASDAQ: BLNK) fell 5 percent to $7.61 in pre-market trading after rising 11.40 percent on Thursday.
    Illumina, Inc. (NASDAQ: ILMN) shares fell 4.7 percent to $255.77 in pre-market trading.
    Vascular Biogenics Ltd (NASDAQ: VBLT) fell 4.6 percent to $2.10 in pre-market trading after reporting a first-quarter earnings miss.
    Campbell Soup Company (NYSE: CPB) fell 3.3 percent to $37.60 in pre-market trading. Campbell Soup reported upbeat Q3 earnings, but sales missed estimates. The company also lowered its FY18 outlook.
    ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares fell 2.7 percent to $17.65 in pre-market trading after reporting a 7.2 million common stock offering

  • [By Dan Caplinger]

    The stock market didn’t see much volatility on Friday, with most major benchmarks finishing the session very close to where they had started. Without much in the way of market-moving news on the national or global front, most investors instead paid attention to the cross-currents involved with monthly options expirations. Some other parts of the financial markets were more interesting, with bond yields easing a bit lower after their big upward push earlier in the week and oil prices taking a break from their recent surge. Yet some individual companies suffered from bad news that sent their shares lower. Baidu (NASDAQ:BIDU), GameStop (NYSE:GME), and Opko Health (NASDAQ:OPK) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Motley Fool Staff]

    In this segment of the Motley Fool Money podcast, host Chris Hill and senior Fool analysts Jason Moser, David Kretzmann, and Jeff Fischer put Baidu (NASDAQ:BIDU) under the microscope. The Chinese search leader has a massive presence in the world’s most populous market, and with revenue up 31%, it’s apparent that it is putting its troubles with the government in Beijing in the rearview mirror. But the stock is still only trading for six times revenue. Time to give it a look?

Hot Blue Chip Stocks To Own For 2019: Astro-Med, Inc.(ALOT)

Advisors’ Opinion:

  • [By Logan Wallace]

    AstroNova (NASDAQ:ALOT) will be issuing its quarterly earnings data before the market opens on Wednesday, August 22nd. Analysts expect the company to announce earnings of $0.12 per share for the quarter.

Hot Blue Chip Stocks To Own For 2019: Stamps.com Inc.(STMP)

Advisors’ Opinion:

  • [By Steve Symington]

    Stamps.com Inc. (NASDAQ:STMP) announced better-than-expected second-quarter 2018 results on Wednesday after the market closed, helped by growth from both its postage and mailing and shipping businesses. The company also closed on one significant acquisition and announced an agreement to purchase an even larger complementary business.

  • [By Ethan Ryder]

    ILLEGAL ACTIVITY WARNING: “Stamps.com (STMP) Given Consensus Recommendation of “Buy” by Analysts” was published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at www.tickerreport.com/banking-finance/3360313/stamps-com-stmp-given-consensus-recommendation-of-buy-by-analysts.html.

  • [By Stephan Byrd]

    Northern Trust Corp increased its stake in shares of Stamps.com Inc. (NASDAQ:STMP) by 5.7% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 249,278 shares of the software maker’s stock after purchasing an additional 13,495 shares during the period. Northern Trust Corp owned approximately 1.37% of Stamps.com worth $63,079,000 at the end of the most recent reporting period.

Hot Blue Chip Stocks To Own For 2019: Alder BioPharmaceuticals, Inc.(ALDR)

Advisors’ Opinion:

  • [By Stephan Byrd]

    BidaskClub cut shares of Alder Biopharmaceuticals (NASDAQ:ALDR) from a strong-buy rating to a buy rating in a report released on Tuesday.

    A number of other equities research analysts have also weighed in on the company. Goldman Sachs Group initiated coverage on Alder Biopharmaceuticals in a research report on Tuesday, April 24th. They set a neutral rating and a $17.00 price objective on the stock. Mizuho restated a buy rating and set a $29.00 price objective on shares of Alder Biopharmaceuticals in a research report on Wednesday, March 28th. Cowen set a $23.00 price target on Alder Biopharmaceuticals and gave the company a buy rating in a research report on Monday, February 26th. Leerink Swann reiterated an outperform rating on shares of Alder Biopharmaceuticals in a research report on Sunday, March 4th. Finally, Zacks Investment Research lowered Alder Biopharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, May 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company. Alder Biopharmaceuticals currently has an average rating of Buy and a consensus target price of $26.33.

  • [By Brian Feroldi]

    Shares of Alder Biopharmaceuticals (NASDAQ:ALDR), a clinical-stage biotech focused on migraines, rose as much as 14% in afternoon trading on Friday. The jump was in response to the news that Teva Pharmaceutical Industries (NYSE:TEVA) is scrapping part of a late-stage study of a potential rival to Alder’s lead compound eptinezumab. Alder’s stock has since cooled off, but was still up about 6% as of 3:58 p.m. EDT.

  • [By Cory Renauer]

    Migraines affect perhaps a billion people the world over, and it’s been three decades since they had a new preventative treatment option. That means there could be enough demand to drive blockbuster sales for a new class of treatments making their way to consumers right now, one of which could come from little Alder Biopharmaceuticals Inc. (NASDAQ:ALDR).

  • [By Joseph Griffin]

    Mizuho reaffirmed their buy rating on shares of Alder Biopharmaceuticals (NASDAQ:ALDR) in a report released on Thursday morning. The brokerage currently has a $29.00 target price on the biopharmaceutical company’s stock.

  • [By Joseph Griffin]

    Alder Biopharmaceuticals Inc (NASDAQ:ALDR) Director Jeffrey T. L. Smith sold 5,040 shares of Alder Biopharmaceuticals stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $18.00, for a total value of $90,720.00. Following the transaction, the director now directly owns 5,871 shares of the company’s stock, valued at approximately $105,678. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

  • [By Ethan Ryder]

    Alder Biopharmaceuticals (NASDAQ:ALDR) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Monday.

Hot Blue Chip Stocks To Own For 2019: Regency Centers Corporation(REG)

Advisors’ Opinion:

  • [By Logan Wallace]

    State of Tennessee Treasury Department raised its holdings in shares of Regency Centers Corp (NYSE:REG) by 402.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 192,496 shares of the real estate investment trust’s stock after purchasing an additional 154,218 shares during the quarter. State of Tennessee Treasury Department’s holdings in Regency Centers were worth $11,353,000 as of its most recent filing with the Securities & Exchange Commission.

  • [By Logan Wallace]

    Fort Washington Investment Advisors Inc. OH purchased a new position in Regency Centers Co. (NYSE:REG) during the first quarter, HoldingsChannel.com reports. The firm purchased 8,200 shares of the real estate investment trust’s stock, valued at approximately $484,000.

  • [By Stephan Byrd]

    These are some of the media headlines that may have effected Accern’s analysis:

    Get Regency Centers alerts:

    Financial Comparison: Regency Centers (REG) vs. CubeSmart (CUBE) (americanbankingnews.com) AlphaGraphics Falls Church Wins Best Operations Award from Franchisor for Continued Managerial Excellence (prnewswire.com) Comparing New Residential Investment (NRZ) & Regency Centers (REG) (americanbankingnews.com) Chimney Rock Shopping Center adds two tenants (njbiz.com) Regency Centers Corp (REG) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)

    A number of research firms recently weighed in on REG. Citigroup upped their target price on shares of Regency Centers from $66.00 to $67.00 and gave the stock a “neutral” rating in a report on Friday, August 17th. Jefferies Financial Group restated a “hold” rating and issued a $67.00 target price on shares of Regency Centers in a report on Wednesday, August 15th. BMO Capital Markets restated a “hold” rating and issued a $62.00 target price on shares of Regency Centers in a report on Thursday, August 2nd. Wells Fargo & Co upped their target price on shares of Regency Centers from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Friday, August 10th. Finally, TheStreet upgraded shares of Regency Centers from a “c+” rating to a “b-” rating in a report on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $68.04.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Regency Centers (REG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *